» Articles » PMID: 35865539

COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review

Overview
Journal Front Immunol
Date 2022 Jul 22
PMID 35865539
Authors
Affiliations
Soon will be listed here.
Abstract

Despite their proven efficacy and huge contribution to the health of humankind, vaccines continue to be a source of concern for some individuals around the world. Vaccinations against COVID-19 increased the number of distressed people and intensified their distrust, particularly as the pandemic was still emerging and the populations were encouraged to be vaccinated under various slogans like "back to normal life" and "stop coronavirus", goals which are still to be achieved. As fear of vaccination-related adverse events following immunization (AEFIs) is the main reason for vaccine hesitancy, we reviewed immune and autoimmune AEFIs in particular, though very rare, as the most worrisome aspect of the vaccines. Among others, autoimmune AEFIs of the most commonly administered COVID-19 vaccines include neurological ones such as Guillain-Barre syndrome, transverse myelitis, and Bell's palsy, as well as myocarditis. In addition, the newly introduced notion related to COVID-19 vaccines, "vaccine-induced immune thrombotic thrombocytopenia/vaccine-induced prothrombotic immune thrombotic thrombocytopenia" (VITT/VIPITT)", is of importance as well. Overviewing recent medical literature while focusing on the major immune and autoimmune AEFIs, demonstrating their rate of occurrence, presenting the cases reported, and their link to the specific type of COVID-19 vaccines represented the main aim of our work. In this narrative review, we illustrate the different vaccine types in current use, their associated immune and autoimmune AEFIs, with a focus on the 3 main COVID-19 vaccines (BNT162b2, mRNA-1273, and ChAdOx1). While the rate of AEFIs is extremely low, addressing the issue in this manner, in our opinion, is the best strategy for coping with vaccine hesitancy.

Citing Articles

ASIA Syndrome: State-of-the-Art and Future Perspectives.

Caldarelli M, Rio P, Giambra V, Gasbarrini A, Gambassi G, Cianci R Vaccines (Basel). 2024; 12(10).

PMID: 39460349 PMC: 11511404. DOI: 10.3390/vaccines12101183.


A case of IgG4-related ophthalmic disease after SARS-CoV-2 vaccination: case report and literature review.

Zhang P, Wu Q, Xu X, Chen M Front Immunol. 2024; 15:1303589.

PMID: 38455056 PMC: 10917890. DOI: 10.3389/fimmu.2024.1303589.


What Is the Impact of the Novel Coronavirus and the Vaccination on Guillain-Barre Syndrome?.

Chen Y, Li K, Lv W, Xie J, Qian Y, Cui C Mol Neurobiol. 2023; 61(12):9835-9850.

PMID: 37728848 DOI: 10.1007/s12035-023-03638-8.


mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis.

Blanco Y, Escudero D, Lleixa C, Llufriu S, Egri N, Garcia R Neurol Neuroimmunol Neuroinflamm. 2023; 10(6).

PMID: 37679040 PMC: 10484689. DOI: 10.1212/NXI.0000000000200163.


Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination.

Jiang M, Yu H, Luo L, Zhang L, Xiong A, Wang J Hum Vaccin Immunother. 2023; 19(2):2246542.

PMID: 37614152 PMC: 10453975. DOI: 10.1080/21645515.2023.2246542.


References
1.
Principi N, Esposito S . Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome. Vaccine. 2018; 37(37):5544-5550. DOI: 10.1016/j.vaccine.2018.05.119. View

2.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao G . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020; 21(1):39-51. PMC: 7561304. DOI: 10.1016/S1473-3099(20)30831-8. View

3.
Masuccio F, Comi C, Solaro C . Guillain-Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report. Acta Neurol Belg. 2021; 122(5):1369-1371. PMC: 8586608. DOI: 10.1007/s13760-021-01838-4. View

4.
Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y . Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021; 385(23):2132-2139. PMC: 8531986. DOI: 10.1056/NEJMoa2110737. View

5.
Ibrahim Ismail I, Salama S . A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2021; 362:577765. PMC: 8577051. DOI: 10.1016/j.jneuroim.2021.577765. View